NCT00046488 - Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

April 30, 2004

Study Completion Date

March 31, 2010

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

IDEC-152

6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4

Trial Locations (6)

Unknown

Research Site, La Jolla

Research Site, Baltimore

Research Site, New Hyde Park

Research Site, New York

Research Site, Columbus

Research Site, Houston